Business Context and Reporting Period
Cognition Therapeutics, Inc. (CGTX), a Delaware corporation and emerging growth company, filed this Form 8-K on September 12, 2024. The company is headquartered in Purchase, NY, and its common stock trades on The Nasdaq Global Market.
Key Financial Metrics
This filing is a current report regarding a listing deficiency and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material event reported is the receipt of a deficiency letter from the Nasdaq Listing Qualifications Department. The letter notified the company that its common stock closing bid price has remained below the minimum $1.00 per share requirement for the last 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Contingencies
- Compliance Period: The company has been granted 180 calendar days, until March 11, 2025, to regain compliance.
- Compliance Criteria: To cure the deficiency, the stock must close at $1.00 per share or more for a minimum of 10 consecutive business days before the deadline.
- Secondary Compliance Option: If the company fails to regain compliance by March 11, 2025, it may be afforded a second 180-day period. This requires transferring to The Nasdaq Capital Market and meeting its initial listing standards (excluding the bid price requirement).
- Delisting Risk: If the company fails to cure the deficiency within the second period or if Nasdaq determines the deficiency cannot be cured, the stock will be subject to delisting. The company may appeal such a determination, though success is not assured.
- Management Action: Management intends to actively monitor the bid price and consider available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of CGTX stock relative to the $1.00 threshold.
- Monitor the company's stock price for 10 consecutive days of trading at or above $1.00 to confirm compliance.
- Review future filings for any announcements regarding a reverse stock split or other capital structure changes intended to raise the share price.
- Check for any updates on the company's intent to transfer to The Nasdaq Capital Market if the initial compliance period expires.